TVM-CAPITAL-HEALTHCARE
28.5.2024 10:02:31 CEST | Business Wire | Press release
TVM Capital Healthcare, an international healthcare expansion and growth capital investor, today announced the closing of the TVM Healthcare Afiyah Fund LP at approximately USD 250 million, its second pool of capital in the Middle East.
TVM Capital Healthcare has operated in the Middle East since 2009 and Southeast Asia since 2021. The new fund builds on the firm’s past success investing in the region, providing highly attractive returns and demonstrating its ability to originate deals and develop successful, sustainable companies with excellent growth prospects and strong management teams.
TVM Capital Healthcare identifies unmet healthcare needs and invests in entrepreneurial companies that create lasting impact in their local communities while delivering strong returns to investors. The firm has built a solid reputation as the first international fund manager investing in and operating major healthcare companies in the Kingdom. It also invests in healthcare growth deals in Europe and the U.S. to support these companies’ expansion plans for Saudi Arabia and the wider GCC. With this two-pronged, highly catalytic strategy, TVM Capital Healthcare optimizes its contribution to transforming the Saudi economy and improves access to world-leading products, technologies, and services in the region.
Among the first investments of the fund are:
- Baraya Extended Care, a Riyadh-based chain of long-term, post-acute care and rehabilitation clinics
- DEBx Medical, an Amsterdam-based developer and manufacturer of ground-breaking products for the treatment of chronic wounds that is about to enter the Saudi market
- neurocare Group, a Munich-based leading innovator in personalized mental health services and products, with clinics in the U.S., the Netherlands, and Australia, that is preparing to enter Saudi and the GCC
Other deals include longevity and genomics, oncology, pharma manufacturing, and diagnostics.
Bandr Alhomaly, Managing Director and CEO of Jada Fund of Funds, said, “The closing of TVM Healthcare Afiyah Fund marks an important milestone in mobilizing private capital into Saudi Arabia's healthcare sector, and we are pleased to lead the investment, providing capital to support the development of the sector in line with Vision 2030."
Dr. Helmut M. Schuehsler, Chairman and CEO of TVM Capital Healthcare added: “We are proud of attracting a distinguished group of institutional and family investment groups from Saudi, other GCC countries, and Europe for a specialist pool of capital of this size being deployed in domestic companies in the Kingdom and international companies entering the market. We are uniquely positioned for success because our leadership team comprises executives with long-standing expertise in Europe and the U.S., who have built excellent international networks throughout their careers, alongside local Saudi healthcare experts. Plus, we have been investing in the GCC and Egypt for over 13 years, and more specifically, operating in Saudi since 2015 through our former portfolio companies, ProVita International Medical Center and Cambridge International Medical Center. Today, we are truly excited about our ability to enhance the local and regional healthcare ecosystem at a much larger scale, helping to improve access to high-quality patient care, medical products, and treatment regimens across the Kingdom.”
TVM Capital Healthcare has offices in Riyadh, Dubai, Singapore and Ho Chi Minh City and supporting offices in Munich and Boston. It was represented in the fundraise by multinational law firm Morgan Lewis.
About TVM Capital Healthcare
TVM Capital Healthcare is an emerging markets-focused healthcare private equity firm headquartered in Dubai and Singapore, with offices in Riyadh and Ho Chi Minh City and supporting offices in Munich and Boston. The firm invests expansion and growth capital in healthcare companies to improve local access to quality care and provide local sources of medical products in the pharma, medical device and diagnostics sectors. Investment and operating partners, as well as a strong group of regional and international senior advisors have long-standing international track records in healthcare investing, active board work, contributions to strategy development and implementation, as well as deep healthcare operating experience in the relevant markets. The firm partners with local Middle Eastern and Southeast Asian management teams to build domestic or regional sector champions and selectively backs companies from Europe or North America for expansion into the firm’s target geographies.
Medical quality of its service businesses is safeguarded by collaborations with leading international medical technology and clinical partners as well as international accreditation agencies such as Joint Commission International (JCI). TVM Capital Healthcare’s investment and operating approach combines strong commercial value creation and financial returns with responsible investing in alignment with the United Nations Sustainable Development Goals (UN SDGs).
www.tvmcapitalhealthcare.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528286443/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 21:44:00 CEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
TOURISE and Oxford Economics Release New Global Report on Tourism Resilience in an Era of Permanent Disruption17.8.2026 16:33:00 CEST | Press release
New analysis shows destinations that assume risk will recover up to 1.5 times faster with global rehabilitation times dropping from 24 months to as little as 10 TOURISE, in collaboration with Oxford Economics, today released a new report, “Resilience in a World that Doesn’t Reset: Redesigning Tourism for an Era of Permanent Disruption.” The analysis of 85 major crises over two decades shows a clear pattern: in a world defined by continuous shocks, destinations that act before disruption hits recover up to 1.5 times faster than those that wait. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817880835/en/ “In a world that does not reset between crises, disruption is a constant feature of the global tourism landscape,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. “The real test for destinations measures how they prepare for volatility, protect traveler confidence, and mai
The Expensify Visa® Commercial Card Brings New Proactive Spend Controls to 14 Countries17.8.2026 15:00:00 CEST | Press release
New admin-defined spend rules let businesses control how, where, and when every card is used, stopping the wrong spend before it happens instead of cleaning it up after. Expensify, Inc. (Nasdaq: EXFY), the easiest way to manage expenses, travel, and corporate cards, today expanded the reach of Expensify Card spend rules, the market-leading way for businesses to control corporate card spend before it happens. Available to businesses in 14 countries, spend rules let admins decide exactly how, where, and when each Expensify Card can be used, so only compliant transactions go through. Unlike traditional corporate cards that rely on after-the-fact expense review, the Expensify Card enforces policy at the point of purchase. Admins set the rules once, and the card handles the rest. With Expensify Card spend rules, admins can: Lock a card to a subscription. Give each recurring SaaS tool its own virtual card, so a vendor can only ever charge what it should. If the card owner changes teams or le
Riskified Analysis Finds Travel Fraudsters Are Adapting Faster Than Traditional Signals Can Keep Up, With May Flight Risk Up 32%17.8.2026 14:30:00 CEST | Press release
New Travel Industry report reveals sophisticated fraud rings are exploiting trusted customer behaviors across flights, hotels, and travel platforms Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released new findings from its Travel Industry Insights report, revealing how sophisticated fraud rings and AI-enabled fraudsters are evolving their tactics across airlines, hotels, and online travel platforms. Riskified’s analysis shows that fraudsters are increasingly adapting their behavior to resemble legitimate travelers, making traditional fraud indicators less reliable and creating new challenges for travel merchants. Riskified’s analysis of hundreds of millions of travel transactions across flights, hotels, and land transportation found that flight fraud risk increased through the first five months of 2026, with May 2026 marking the sharpest year-over-year increase at 32% compared to May 2025. The findings show that sophisticated fraud activity i
PIF Delivers Strong Revenue and Profit Growth in 202517.8.2026 13:54:00 CEST | Press release
Revenue rose 9% to $120 billion while net profit more than doubled to $17 billionCumulative domestic investments reached more than $199 billion since 2021PIF has contributed more than $342 billion to Saudi Arabia’s real non-oil GDP between 2021 and 2025Assets under management exceed $900 billion, up from around $530 in 2021 and $150 billion in 2015 PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year on year to $120 billion, while net profit more than doubled to $17 billion, supported by stronger contributions from maturing portfolio companies. PIF retained over $900 billion in assets
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom